Company profile for BioInvent

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Based on its insights in immunology, cancer biology and antibody biology, BioInvent aims to develop cancer immunotherapies to improve the quality of life for cancer patients. BioInvent’s strategy is to leverage its expertise in antibodies and cancer biology to develop immuno-oncology drugs that significantly improve the treatment of cancer diseases and prolong cancer patients' lives. This is accomplished through collaboratio...
Based on its insights in immunology, cancer biology and antibody biology, BioInvent aims to develop cancer immunotherapies to improve the quality of life for cancer patients. BioInvent’s strategy is to leverage its expertise in antibodies and cancer biology to develop immuno-oncology drugs that significantly improve the treatment of cancer diseases and prolong cancer patients' lives. This is accomplished through collaborations with large pharmaceutical companies, academic research groups, networks of clinical specialists and research foundations.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
Sweden
Address
Address
Ideon Science Park SE-223 70 Lund
Telephone
Telephone
+46 (0)46-286 85 50
youtube
YouTube

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Tides Asia

Tides Asia

Not Confirmed

envelop Contact Supplier

Tides Asia

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.pharmiweb.com/press-release/2025-12-07/bioinvent-presents-promising-early-phase-2a-bi-1808-monotherapy-data-in-ctcl-at-ash-2025

PHARMIWEB
07 Dec 2025

https://www.pharmiweb.com/press-release/2025-11-18/bioinvent-announces-publication-of-preclinical-and-early-phase-1-data-for-bi-1607-in-her2-positive-a

PHARMIWEB
18 Nov 2025

https://www.pharmiweb.com/press-release/2025-11-17/ema-positive-opinion-for-orphan-drug-designation-to-bioinvents-bi-1808-for-the-treatment-of-cutaneo

PHARMIWEB
17 Nov 2025

https://www.pharmiweb.com/press-release/2025-11-07/bioinvents-bi-1910-data-validates-tnfr2-as-a-novel-immunotherapy-approach-in-advanced-solid-tumors

PHARMIWEB
07 Nov 2025

https://www.pharmiweb.com/press-release/2025-11-03/bioinvent-to-present-updated-phase-2a-bi-1808-monotherapy-data-in-ctcl-at-ash-2025

PHARMIWEB
03 Nov 2025

https://www.pharmiweb.com/press-release/2025-11-03/bioinvent-to-present-early-phase-2a-data-from-ongoing-trial-with-triple-combination-of-bi-1206-ritu

PHARMIWEB
03 Nov 2025

REF. STANDARDS & IMPURITIES

Upload your portfolio for free, ask us

ABOUT THIS PAGE

Contact BioInvent and get a quotation

BioInvent is a supplier offers 1 products (APIs, Excipients or Intermediates).

Find a price of MONOCLONAL ANTIBODY PRODUCTION bulk offered by BioInvent

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty